A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines

This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine patients who have received a minimum of 7 treatment cycles.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Migraine, Headaches Headache Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Encinitas, California, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

15 or more headache days over a 30 day period
A minimum of 7 treatment cycles with onabotulinumtoxinA

Exclusion criteria

Any treatment cycle dose of onabotulinumtoxinA greater than 200 units

Treatment and study plan

onabotulinumtoxinA

Biological

Previous treatment with onabotulinumtoxinA for Chronic Migraine.

Other names: Botulinum Toxin Type A, BOTOX®

Primary outcomes

Change From Baseline in the Number of Headache Days

Time frame: Treatment Cycle 7 (approximately 1.5 years)

The mean number of headache days was counted as the number of headache days occurring during the 30 day period ending with treatment cycle 7. Each treatment cycle was administered approximately every 12 weeks.

Sponsors and collaborators

Lead sponsor

Allergan

Industry

Registry information

Important dates

Study start: 2013
Primary completion: 2014
Study completion: 2014
First posted: Dec 13, 2012
Registry last updated: Sep 10, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed